Developing novel, orally administered ophthalmology drugs to meet the needs of millions of patients suffering vision loss.
Addressing the large unmet medical need to develop more effective and less burdensome therapies for patients and their caregivers.
Developing danegaptide, an orally administered, small molecule drug with a novel mode of action.
Developing orally administered P2X7 receptor antagonists with anti-inflammatory and neuroprotective properties.
Breye Therapeutics ApS
Agern Allè 24